Omnitrope and Cellulitis - a phase IV clinical study of FDA data

Summary:

Cellulitis is reported as a side effect among people who take Omnitrope (somatropin recombinant), especially for people who are male, 20-29 old, have been taking the drug for < 1 month also take Menopur, and have Blood thyroid stimulating hormone decreased.

The phase IV clinical study analyzes which people have Cellulitis when taking Omnitrope. It is created by eHealthMe based on reports of 8,562 people who have side effects when taking Omnitrope from the FDA, and is updated regularly.

What is Omnitrope?

Omnitrope has active ingredients of somatropin recombinant. It is often used in growth hormone deficiency. eHealthMe is studying from 8,582 Omnitrope users. Check the latest studies of Omnitrope.

What is Cellulitis?

Cellulitis (infection under the skin) is found to be associated with 2,078 drugs and 2,341 conditions by eHealthMe. Check the latest studies of Cellulitis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

8,562 people reported to have side effects when taking Omnitrope.
Among them, 15 people (0.18%) have Cellulitis.

Among these 15 people:

How long have people been on Omnitrope when they have Cellulitis? *

What is the gender of people who have Cellulitis when taking Omnitrope? *

female: 42.86 %
male: 57.14 %

What is the age of people who have Cellulitis when taking Omnitrope? *

What are other drugs people take besides Omnitrope? *

Vitamin D: 2 people, 13.33%
Pregnyl: 2 people, 13.33%
Menopur: 2 people, 13.33%

What are other side effects people have besides Cellulitis? *

Joint Pain: 4 people, 26.67%
Joint Swelling: 3 people, 20.00%
Arthritis Bacterial (form of joint disorder that involves inflammation of one or more joints due to bacterial infection): 3 people, 20.00%
Bursitis (inflammation of a bursa, typically one in the knee, elbow, or shoulder): 3 people, 20.00%
Joint Effusion (presence of extra fluid in joint covering): 3 people, 20.00%
Weight Decreased: 2 people, 13.33%
Dizziness: 2 people, 13.33%
Fatigue (feeling of tiredness): 2 people, 13.33%
Hypoaesthesia (reduced sense of touch or sensation): 2 people, 13.33%
Weakness: 2 people, 13.33%

What are the existing conditions these people have? *

Diabetes Insipidus (diabetes caused by a deficiency of the pituitary hormone vasopressin, which regulates kidney function): 3 people, 20.00%
Blood Thyroid Stimulating Hormone Decreased: 3 people, 20.00%
Hypopituitarism (diminished hormone secretion by the pituitary gland, causing dwarfism in children and premature aging in adults): 2 people, 13.33%
Autism Spectrum Disorder (developmental disabilities that can cause significant social, communication and behavioural challenges): 2 people, 13.33%
Small For Dates Baby (an unborn baby is growing more slowly and is smaller than most babies are at the same age): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Omnitrope and have Cellulitis?

- Check whether Cellulitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Omnitrope:

Omnitrope (8,582 reports)

Cellulitis treatments and more:

Cellulitis (75,291 reports)

Browse all side effects of Omnitrope:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Cellulitis:

Cellulitis (2,078 drugs)

Browse all the conditions that are associated with Cellulitis:

Cellulitis (2,341 conditions)

Related publications that referenced our studies

Yaylaci S, Yilmaz EU, Guclu E, Kumsar NA, Tamer A, Karabay O, "Clozapine-Induced Febrile Neutropenia and Cellulitis", Turkish journal of emergency medicine, 2014 Mar .
Yaylaci S, Yilmaz EU, Guclu E, Kumsar NA, Tamer A, Karabay O, "Clozapine-Induced Febrile Neutropenia and Cellulitis", Turkish journal of emergency medicine, 2014 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on somatropin recombinant (the active ingredients of Omnitrope) and Omnitrope (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.